Therapeutic Area
2023
ROSELLA (GOG-3073, ENGOT-OV72/MITO): A Phase 3 Study of Relacorilant + Nab-paclitaxel vs. Nab-paclitaxel in Platinum-Resistant Ovarian Cancer
International Gynecologic Cancer Society (IGCS) Annual Global Meeting
2023
PosterROSELLA, GOG‑3073, ENGOT‑OV72/MITO: A Phase 3 Study of Relacorilant + Nab‑paclitaxel vs. Nab‑paclitaxel in Advanced, Platinum-resistant Ovarian Cancer
European Society of Gynaecological Oncology (ESGO) Congress
2023
PresentationSelective Glucocorticoid Receptor Modulation Reveals a New Role for CLEC10A in Patients With Solid Tumors
American Association for Cancer Research (AACR) Annual Meeting
2023
PosterROSELLA, GOG‑3073, ENGOT‑OV72/MITO: A Phase 3 Study of Relacorilant + Nab‑paclitaxel vs. Nab‑paclitaxel in Advanced, Platinum-resistant Ovarian Cancer
Society of Gynecologic Oncology (SGO) Annual Meeting
2023
PosterPhase 1 Efficacy and Pharmacodynamic Results of Exicorilant + Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium
2023